While inhibitors like A-419259 and TL02-59 target Src family kinases such as Hck and Fgr, acquired resistance remains a significant challenge (Yang et al., 2022; Negi et al., 2021), underscoring the need for novel inhibitors to improve AML outcomes. This evidence concerns the gene HCK and acute myeloid leukemia.